- Open Access
Biomarkers of cardio-renal damage in chronic kidney disease: one size cannot fit all
Critical Carevolume 18, Article number: 134 (2014)
Biomarkers are useful tools for diagnosis and risk assessment of acute kidney injury and acute heart failure, particularly in ICU patients. Most biomarkers are produced or cleared by the kidney, so the presence of chronic kidney disease may affect their clinical reliability, particularly if the putative diagnosis of acute kidney injury or acute heart failure is based on a single measurement/single threshold approach. Better alternatives, such as establishing different diagnostic cutoff values per different chronic kidney disease strata or evaluating the diagnostic performance of a delta value (change from baseline levels) instead of a single threshold, should be carefully considered in critically ill patients with renal impairment and other co-morbidities.
Chronic kidney disease (CKD) is highly prevalent in the ICU population and conveys a higher risk of developing both acute kidney injury (AKI) and acute heart failure (AHF). Early serum and urine biomarkers of AKI and AHF may improve diagnosis and risk stratification. Most biomarkers are affected by renal function impairment, however, so the presence of CKD may hamper their predictive capacity.
Donadio investigated whether the presence of underlying CKD may affect the diagnostic performance of two of the most studied biomarkers of cardio-renal damage, namely neutrophil gelatinase-associated lipocalin (NGAL) and brain natriuretic peptide (BNP) . In this study, plasma NGAL increased in a parallel fashion with the reduction in glomerular filtration rate (GFR), generating a very high number of false positive diagnoses of AKI in stable CKD patients. Conversely, urinary NGAL and plasma BNP were less affected by reduced GFR.
NGAL is a kidney stress protein, the levels of which increase in plasma and urine of patients developing AKI, 2 to 8 hours after renal injuries of various nature . Although the predictive performance of NGAL was remarkable in pediatric populations, conflicting results emerged in the adult setting. In particular, studies reporting an excellent discriminant ability mostly excluded patients with preoperative CKD, whereas a more modest performance was reported in those also including patients with impaired renal function . In CKD patients, NGAL levels are strictly, independently and inversely correlated to residual GFR, probably as the consequence of an active production by the damaged but still vital tubule that goes along with the functional decrease of renal parenchyma .
The effect of baseline renal function on the diagnostic performance of urinary NGAL was also evaluated recently by McIlroy and colleagues in a prospective observational study in 426 adults undergoing major cardiac surgery . In patients with baseline GFR >60 ml/minute who developed AKI, urinary NGAL was higher at all postoperative time points compared with those patients who did not have this complication. Conversely, no differences were reported in patients with baseline GFR <60 ml/minute. Postoperative NGAL best identified AKI in patients with baseline GFR 90 to 120 ml/minute, therefore suggesting that the optimal discriminatory performance is achieved in patients with normal preoperative renal function.
As is well known, BNP is mostly useful for screening and prognosis of acute and chronic heart dysfunction. Although less than 5% of BNP is cleared by the renal route, accruing evidence indicates that the circulating levels of this biomarker are elevated in CKD patients despite an apparently conserved ventricular function [6, 7]. In addition, elevated BNP levels predict accelerated progression of CKD in patients with mild to moderate renal impairment, independently from cardiac (dys)function . Although BNP levels could therefore be helpful in the management of combined heart and kidney disease, these observations might raise concerns regarding the specificity of BNP as biomarker of AHF in the scenario of CKD. Challenging the issue of baseline renal function is thus crucial for validating the potential usefulness of biomarkers in clinical practice. Even the measurement of widely implemented biomarkers, such as troponins or tumor markers [9, 10], often leads to misleading clinical interpretations in CKD (especially dialysis) patients.
For biomarkers of AKI and AHF, we believe that, as a general rule, one size (that is, one threshold) cannot fit all. In other words, it is virtually impossible to consider univocal cutoff values able to stratify the risk of AKI or AHF in a miscellaneous population of critically ill patients as a whole. Considering different diagnostic thresholds for different CKD strata might help to improve the overall performance of NGAL and BNP but, predictably, this would not reduce the ground noise caused by other confounders. For instance, apart from renal damage, NGAL levels are known to be affected also by proteinuria, systemic inflammation, oxidative stress, iron balance, diabetes and existing cardiovascular disease , while BNP can be influenced by chronic heart failure, obesity, inflammation and even age, gender and heart rate . This variation makes it virtually impossible to find baseline values of these biomarkers falling within the normal range, even in ICU patients with normal renal function or early stage CKD. In view of this, a single-time, threshold-based measurement of NGAL or BNP as an exclusive tool for predicting AKI or AHF should probably be called into question. Even if a cost–benefit analysis must always be taken into account, it would be good to verify whether the predictive capacity of a delta value (variation in biomarkers levels between end of procedure and baseline; for example, time of admission in the ICU) would be superior to that of a single biomarker measurement.
In conclusion, the presence of CKD may actually impact upon the diagnostic performance and reliability of biomarkers of acute damage of kidney and heart. This holds true for biomarkers already used in daily clinical practice as well as for those emerging biomarkers whose promising, preliminary findings in homogeneous study cohorts still await an external validation. Since CKD is exceedingly prevalent in ICU patients, taking systematically into account the effect of residual renal function might enhance the diagnostic performance of biomarkers for the risk stratification of cardio-renal complications in critically ill patients.
Acute heart failure
Acute kidney injury
Brain natriuretic peptide
Chronic kidney disease
Glomerular filtration rate
Neutrophil gelatinase-associated lipocalin.
Donadio C: Effect of glomerular filtration rate impairment on diagnostic performance of neutrophil gelatinase-associated lipocalin and B-type natriuretic peptide as markers of acute cardiac and renal failure in chronic kidney disease patients. Crit Care 2014, 18: R39. 10.1186/cc13752
Di Grande A, Giuffrida C, Carpinteri G, Narbone G, Pirrone G, Di Mauro A, Calandra S, Noto P, Le Moli C, Alongi B, Nigro F: Neutrophil gelatinase-associated lipocalin: a novel biomarker for the early diagnosis of acute kidney injury in the emergency department. Eur Rev Med Pharmacol Sci 2009, 13: 197-200.
Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A, NGAL Meta-analysis Investigator Group: Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009, 54: 1012-1024. 10.1053/j.ajkd.2009.07.020
Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, Buemi M: Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008, 52: 595-605. 10.1053/j.ajkd.2008.01.020
McIlroy DR, Wagener G, Lee HT: Neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery: the effect of baseline renal function on diagnostic performance. Clin J Am Soc Nephrol 2010, 5: 211-219. 10.2215/CJN.04240609
Austin WJ, Bhalla V, Hernandez-Arce I, Isakson SR, Beede J, Clopton P, Maisel AS, Fitzgerald RL: Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am J Clin Pathol 2006, 126: 506-512. 10.1309/M7AAXA0J1THMNCDF
Jafri L, Kashif W, Tai J, Siddiqui I, Azam I, Shahzad H, Ghani F: B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function. BMC Nephrol 2013, 14: 117. 10.1186/1471-2369-14-117
Yasuda K, Kimura T, Sasaki K, Obi Y, Iio K, Yamato M, Rakugi H, Isaka Y, Hayashi T: Plasma B-type natriuretic peptide level predicts kidney prognosis in patients with predialysis chronic kidney disease. Nephrol Dial Transplant 2012, 27: 3885-3891. 10.1093/ndt/gfs365
Coppolino G: Focus on high sensitivity cardiac troponin tests in patients with altered renal function. G Ital Nefrol 2011, 28: 138.
Coppolino G, Bolignano D, Rivoli L, Presta P, Fuiano G: Tumour markers and kidney function: a systematic review. Biomed Res Int 2014. Epub ahead of print. [http://dx.doi.org/10.1155/2014/647541] Epub ahead of print. 
Bolignano D, Coppolino G, Lacquaniti A, Buemi M: From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. Eur J Clin Invest 2010, 40: 273-276. 10.1111/j.1365-2362.2010.02258.x
Clerico A, Giannoni A, Vittorini S, Passino C: Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol 2011, 301: H12-H20. 10.1152/ajpheart.00226.2011
The authors declare that they have no competing interests.